Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 312

1.

The Vasculature in Prediabetes.

Wasserman DH, Wang TJ, Brown NJ.

Circ Res. 2018 Apr 13;122(8):1135-1150. doi: 10.1161/CIRCRESAHA.118.311912. Review.

PMID:
29650631
2.

Ethnic differences in the progression of chronic kidney disease and risk of death in a UK diabetic population: an observational cohort study.

Mathur R, Dreyer G, Yaqoob MM, Hull SA.

BMJ Open. 2018 Mar 27;8(3):e020145. doi: 10.1136/bmjopen-2017-020145.

3.

Evolution of Diabetes Care in Hong Kong: From the Hong Kong Diabetes Register to JADE-PEARL Program to RAMP and PEP Program.

Ng IHY, Cheung KKT, Yau TTL, Chow E, Ozaki R, Chan JCN.

Endocrinol Metab (Seoul). 2018 Mar;33(1):17-32. doi: 10.3803/EnM.2018.33.1.17. Review.

4.

Early and late scanning electron microscopy findings in diabetic kidney disease.

Conti S, Perico N, Novelli R, Carrara C, Benigni A, Remuzzi G.

Sci Rep. 2018 Mar 20;8(1):4909. doi: 10.1038/s41598-018-23244-2.

5.

Cardiovascular and renal protective role of angiotensin blockade in hypertension with advanced CKD: a subgroup analysis of ATTEMPT-CVD randomized trial.

Kim-Mitsuyama S, Soejima H, Yasuda O, Node K, Jinnouchi H, Yamamoto E, Sekigami T, Ogawa H, Matsui K.

Sci Rep. 2018 Feb 16;8(1):3150. doi: 10.1038/s41598-018-20874-4.

6.

Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial.

Borg R, Persson F.

Ann Transl Med. 2017 Dec;5(23):478. doi: 10.21037/atm.2017.11.02. No abstract available.

7.

FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.

Kim JY, Son JW, Park S, Yoo TH, Kim YJ, Ryu DR, Chin HJ.

Trials. 2017 Dec 29;18(1):632. doi: 10.1186/s13063-017-2375-8.

8.

A non-laboratory-based risk score for predicting diabetic kidney disease in Chinese patients with type 2 diabetes.

Wu M, Lu J, Zhang L, Liu F, Chen S, Han Y, Zhao F, Guo K, Bao Y, Chen H, Jia W.

Oncotarget. 2017 Oct 9;8(60):102550-102558. doi: 10.18632/oncotarget.21684. eCollection 2017 Nov 24.

9.

Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients.

Vejakama P, Ingsathit A, McKay GJ, Maxwell AP, McEvoy M, Attia J, Thakkinstian A.

BMC Nephrol. 2017 Nov 29;18(1):342. doi: 10.1186/s12882-017-0753-9.

10.

Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis.

Brunström M, Carlberg B.

JAMA Intern Med. 2018 Jan 1;178(1):28-36. doi: 10.1001/jamainternmed.2017.6015.

PMID:
29131895
11.

Effect of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease: A randomized controlled trial.

Piovesan F, Tres GS, Moreira LB, Andrades ME, Lisboa HK, Fuchs SC.

PLoS One. 2017 Oct 19;12(10):e0186554. doi: 10.1371/journal.pone.0186554. eCollection 2017.

12.

Diabetic Nephropathy: a Tangled Web to Unweave.

Magee C, Grieve DJ, Watson CJ, Brazil DP.

Cardiovasc Drugs Ther. 2017 Dec;31(5-6):579-592. doi: 10.1007/s10557-017-6755-9. Review.

13.

Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care - The NephroTest study.

Wagner S, Metzger M, Flamant M, Houillier P, Haymann JP, Vrtovsnik F, Thervet E, Boffa JJ, Massy ZA, Stengel B, Rossignol P; NephroTest Study group.

BMC Nephrol. 2017 Sep 12;18(1):295. doi: 10.1186/s12882-017-0710-7. Erratum in: BMC Nephrol. 2017 Oct 6;18(1):308.

14.

Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM).

Bertoluci MC, Moreira RO, Faludi A, Izar MC, Schaan BD, Valerio CM, Bertolami MC, Chacra AP, Malachias MVB, Vencio S, Saraiva JFK, Betti R, Turatti L, Fonseca FAH, Bianco HT, Sulzbach M, Bertolami A, Salles JEN, Hohl A, Trujilho F, Lima EG, Miname MH, Zanella MT, Lamounier R, Sá JR, Amodeo C, Pires AC, Santos RD.

Diabetol Metab Syndr. 2017 Jul 14;9:53. doi: 10.1186/s13098-017-0251-z. eCollection 2017. Review.

15.

Renal Consequences of Diabetes After Kidney Donation.

Ibrahim HN, Berglund DM, Jackson S, Vock DM, Foley RN, Matas AJ.

Am J Transplant. 2017 Dec;17(12):3141-3148. doi: 10.1111/ajt.14416. Epub 2017 Aug 14.

PMID:
28681494
16.

Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes - A comparative study of two markers to identify high risk patients.

Broedbaek K, Køster-Rasmussen R, Siersma V, Persson F, Poulsen HE, de Fine Olivarius N.

Redox Biol. 2017 Oct;13:363-369. doi: 10.1016/j.redox.2017.06.005. Epub 2017 Jun 15.

17.

Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging.

Ismail B, deKemp RA, Croteau E, Hadizad T, Burns KD, Beanlands RS, DaSilva JN.

PLoS One. 2017 May 19;12(5):e0177451. doi: 10.1371/journal.pone.0177451. eCollection 2017.

18.

Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.

Giles TD, Cockcroft JR, Pitt B, Jakate A, Wright HM.

J Hypertens. 2017 Sep;35(9):1758-1767. doi: 10.1097/HJH.0000000000001412. Review.

19.

Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease.

Wysocki J, Goodling A, Burgaya M, Whitlock K, Ruzinski J, Batlle D, Afkarian M.

Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F487-F494. doi: 10.1152/ajprenal.00074.2017. Epub 2017 May 3.

PMID:
28468961
20.

The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis.

Liao KM, Cheng HT, Lee YH, Chen CY.

Medicine (Baltimore). 2017 Mar;96(13):e6525. doi: 10.1097/MD.0000000000006525.

Supplemental Content

Support Center